Castle Biosciences. has been granted a patent for a method to assess the risk of metastasis in cutaneous squamous cell carcinoma (cSCC) by analyzing the expression of 34 specific genes. This method aids in determining aggressive treatment options to improve patient outcomes. GlobalData’s report on Castle Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Castle Biosciences, Personalized medicine biomarkers was a key innovation area identified from patents. Castle Biosciences's grant share as of June 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.
Method for predicting and treating high-risk cscc tumors
The patent US11976331B2 outlines a method for treating patients diagnosed with cutaneous squamous cell carcinoma (cSCC) by assessing the risk of metastasis through the expression levels of a specific set of 34 genes. The process involves obtaining a tumor sample, measuring the expression levels of these genes, and comparing them to a predictive training set to generate a probability score indicating the risk of metastasis. Based on this score, which can classify patients into low, moderate, or high-risk categories, appropriate aggressive treatment options are administered. These treatments may include radiation therapy, chemotherapy, immunotherapy, or surgical interventions aimed at improving relapse-free survival for patients identified as having a high risk of metastasis.
Additionally, the method allows for the inclusion of control genes to enhance the accuracy of the risk assessment. The expression levels of the genes are determined using reverse transcription and nucleic acid detection systems. The patent also specifies that the tumor samples can be obtained from formalin-fixed, paraffin-embedded tissues. The treatment regimen can be tailored based on the risk classification, with the potential for resection of the tumor in high-risk cases. This innovative approach aims to provide a more personalized treatment strategy for patients with cSCC, potentially leading to better clinical outcomes.
To know more about GlobalData’s detailed insights on Castle Biosciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
